NCCN Flash Update: NCCN Guidelines Updated
Flash Update Sent April 8, 2011
NCCN has published updates to the NCCN Guidelines for Hodgkin Lymphoma. These NCCN Guidelines are currently available as Version 1.2011.
- For patients with Stage IA, IIA favorable disease, 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by 20 Gy IFRT was added as a primary treatment option for patients with ESR less than 50, no extralymphatic lesions and only one or two nodal sites involved.
- The recommendations for Progressive Disease and Relapse were separated. Relapse was changed to "Suspected Relapse" with the first treatment recommendation of rebiopsy.
- The combination regimen of GCD (gemcitabine, carboplatin, dexamethasone) was added as an option for second-line chemotherapy prior to transplant.
Flash Update Sent May 6, 2011
NCCN has published updates to the NCCN Guidelines for Hodgkin Lymphoma. These NCCN Guidelines are currently available as Version 2.2011.
The Discussion section of the NCCN Guidelines for Hodgkin Lymphoma has been updated to correspond with the treatment algorithm.
The following references were added for ABVD on the Principles of Systemic Therapy for Lymphocyte-predominant Hodgkin Lymphoma:
- Savage KJ, Skinnider B, Al Mansour M, et al. Incorporation of ABVD increases cure rates of patients with limited stage nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) [abstract]. Blood 2010;116:Abstract 3887.
- Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's Lymphoma? J Clin Oncol 2010;28:e8.
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.